A Phase 3 interventional study of Ravulizumab and Best Supportive Care in Thrombotic Microangiopathy, sponsored by Alexion Pharmaceuticals, Inc.. Completed at 26 sites in 7 countries. Open to participants aged Up to 17 Years. Per ClinicalTrials.gov, last updated 2026-01-12.
Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Thrombotic Microangiopathies with a site in United States — 3 open to participants now, 3 under way, none of them phase 3. Thrombotic Microangiopathies · United States.
Among the 20 studies in Thrombotic Microangiopathies with a site in United States, this one is the 4th largest by enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2020, is one of 7 in phase 3, and was the 11th registered.
52 studies on the registry are indexed under Thrombotic Microangiopathies; 21 are open to participants now.
Browse Thrombotic Microangiopathies studies →3 of the 20 studies in Thrombotic Microangiopathies with a site in United States are open now. Recruiting first, the newest first:
Omeros Corporation · Sites in United States, Germany, Israel and 2 more countries
Ages 28 days–17 yrs
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages up to 24
Alexion Pharmaceuticals, Inc. · Sites in United States, Australia, Belgium and 14 more countries
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 19 Thrombotic Microangiopathies studies recruiting now, 13 (68%) set no upper age limit and 3 (16%) stop at 75 or younger; 9 take children under 18; 1 takes healthy volunteers.
This study: Up to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 3 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 41 is close to the median of 40 across 24 interventional studies indexed under Thrombotic Microangiopathies.
Median enrollment 24 across the 14 interventional studies, 254 across the 6 observational. Of the 14 that completed or were terminated, 9 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 20 have an industry lead sponsor. The 10 most frequent:
This study is registered under Alexion Pharmaceuticals, Inc., one of the names counted as AstraZeneca. Under that name alone:
Alexion Pharmaceuticals, Inc. is the lead sponsor of 255 studies on the registry; 23 are open to participants now.
Of its 101 completed or terminated interventional studies of FDA-regulated products, 75 (74%) have results posted.
AstraZeneca has 6 studies filed under Thrombotic Microangiopathies — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 20 studies in Thrombotic Microangiopathies with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of ravulizumab administered by intravenous infusion to pediatric participants, from 1 month to \< 18 years of age, with HSCT-TMA. The treatment period is 26 weeks, followed by a 26-week off-treatment follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive ravulizumab plus Best Supportive Care as background therapy.
Drug: Ravulizumab · Other: Best Supportive Care
Weight-based doses of ravulizumab will be administered intravenously as a loading dose regimen followed by maintenance dosing every 4 or 8 weeks, depending upon weight.
Also known as: Ultomiris
Participants will receive medications, therapies, and interventions per standard hospital treatment protocols (unless specifically prohibited by the protocol).
Participants With Thrombotic Microangiopathy (TMA) Response
The criteria for TMA response were: 1. Normalization of platelet count (defined as platelet count ≥ 50000 mm\^3 or \>=50% increase in platelet count) without transfusion support during the prior 7 days. 2. Normalization of lactate dehydrogenase (LDH, defined as LDH ≤ upper limit of normal \[ULN\]) and absence of schistocytes. 3. At least 50% reduction in protein/creatinine ratio from baseline. Participants must meet each TMA criterion at 2 separate assessments obtained at least 24 hours apart, with no criteria failures or more than 1 missed scheduled visit in between. Additionally, all intervals in which the criteria were met must overlap for at least 1 day.
Time frame: Up to Week 26
Time to TMA Response During the 26-Week Treatment Period
Time to TMA response was defined as the time from first infusion to the first time point at which all criteria for TMA response was met. Participants were assigned as responders at the time of their TMA response and were censored at the earlier of last assessment with all 3 TMA response components available (including measurements collected after treatment discontinuation), or death if they did not respond by then. TMA response required the following: 1. Normalization of platelet count (defined as platelet count ≥ 50000 mm\^3 or \>=50% increase in platelet count) without transfusion support during the prior 7 days. 2. Normalization of LDH (defined as LDH ≤ULN) and absence of schistocytes. 3. At least 50% reduction in protein/creatinine ratio from baseline.
Time frame: Day 1 through Week 26
Participants With Hematologic Response
Hematologic response required the following: (1) Normalization of platelet count (defined as platelet count ≥ 50000 mm\^3 or \>=50% increase in platelet count) without transfusion support during the prior 7 days and (2) Normalization of LDH (defined as LDH ≤ULN) and absence of schistocytes.
Time frame: Up to Week 26
Time to Hematologic Response During the 26-Week Treatment Period
Time to Hematologic response was defined as the time from first infusion to the first time point at which all criteria for hematologic response was met. Participants were assigned as responders at the time of their response and were censored at their discontinuation time or at the end of available follow-up if they did not respond by then. Hematologic response required the following: (1) Normalization of platelet count (defined as platelet count ≥ 50000 mm\^3 or \>=50% increase in platelet count) without transfusion support during the prior 7 days and (2) Normalization of LDH (defined as LDH ≤ULN) and absence of schistocytes.
Time frame: Day 1 through Week 26
Participants With Hemoglobin Response
Hemoglobin response was defined as the ability to maintain hemoglobin ≥ 10 g/dL without RBC transfusion support. The criterion must have been met at 2 separate assessments obtained at least 24 hours apart, and any measurement in between, and without RBC transfusion support during the prior 7 days.
Time frame: Up to Week 26
Participants With Platelet Response
Normalization of platelet count was defined as baseline platelet count ≤ 50000 mm\^3 or \> 50000 mm\^3, absolute platelet count \> 50000 mm\^3 or \>=50% increase in platelet count without transfusion support during the prior 7 days.
Time frame: Up to Week 26
Participants With Partial TMA Response
Partial response was defined as a participant meeting at least 1, but not all, criteria for TMA response. TMA response required the following: 1. Normalization of platelet count (defined as platelet count ≥ 50000 mm\^3 or \>=50% increase in platelet count) without transfusion support during the prior 7 days. 2. Normalization of LDH, (defined as LDH ≤ULN) and absence of schistocytes. 3. At least 50% reduction in protein/creatinine ratio from baseline.
Time frame: Up to Week 26
Participants With Loss of TMA Response
Loss of response occurred when a participant who had previously achieved a TMA response failed to meet criteria for one or more components of TMA response at a subsequent visit in treatment period. At least one parameter must fail to meet response criteria at 2 separate assessments obtained at least 24 hours apart, and any measurement in between. TMA response required the following: 1. Normalization of platelet count (defined as platelet count ≥ 50000 mm\^3 or \>=50% increase in platelet count) without transfusion support during the prior 7 days. 2. Normalization of LDH (defined as LDH ≤ULN) and absence of schistocytes. 3. At least 50% reduction in protein/creatinine ratio from baseline.
Time frame: Up to Week 26
Duration of TMA Response Through Week 52
This analysis includes data for each participant after TMA response through final follow-up. Participants with TMA response who do not experience these events are censored at their end of study date. TMA response required following: 1. Normalization of platelet count (defined as platelet count ≥ 50000 mm\^3 or \>=50% increase in platelet count) without transfusion support during the prior 7 days. 2. Normalization of LDH (defined as LDH ≤ULN) and absence of schistocytes. 3. At least 50% reduction in protein/creatinine ratio from baseline. The estimate is calculated based on Kaplan-Meier method.
Time frame: Day 1 through Week 52
Participants With TMA Relapse
For participants that meet criteria for TMA response during 26-week Treatment Period, TMA relapse is defined as evidence of worsening hematologic and renal dysfunction due to TMA during post-treatment Follow-up Period that requires treatment intervention, as determined by Investigator. TMA response required the following: 1. Normalization of platelet count (defined as platelet count ≥ 50000 mm\^3 or \>=50% increase in platelet count) without transfusion support during the prior 7 days. 2. Normalization of LDH (defined as LDH ≤ULN) and absence of schistocytes. 3. At least 50% reduction in protein/creatinine ratio from baseline.
Time frame: Up to Week 52
Overall Survival
The Kaplan-Meier method was used to measure overall survival estimate. Overall survival was calculated from date of treatment start to date of a documented death event (death due to any cause) or date of censoring. Participants who survived were censored at the earliest of an additional hematopoietic stem cell transplant (HSCT), Week 52, or their last known date alive.
Time frame: Day 1 through Week 52
Non-relapse Mortality During the 52-Week Treatment Period
Cumulative incidence was estimated using a competing risk model. Non-relapse mortality was defined as a participant's death due to any cause during the study, with the exception of death due to underlying disease progression or relapse.
Time frame: Day 1 through Week 52
| Milestone | Ravulizumab |
|---|---|
| Started | 41 |
| Received at least 1 dose of study drug | 41 |
| Completed | 29 |
| Not completed | 12 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Physician decision | 4 |
| Withdrew: Death | 5 |
| Withdrew: Adverse event | 2 |
| Milestone | Ravulizumab |
|---|---|
| Started | 29 |
| Completed | 24 |
| Not completed | 5 |
| Withdrew: Physician decision | 1 |
| Withdrew: Death | 4 |
The criteria for TMA response were: 1. Normalization of platelet count (defined as platelet count ≥ 50000 mm\^3 or \>=50% increase in platelet count) without transfusion support during the prior 7 days. 2. Normalization of lactate dehydrogenase (LDH, defined as LDH ≤ upper limit of normal \[ULN\]) and absence of schistocytes. 3. At least 50% reduction in protein/creatinine ratio from baseline. Participants must meet each TMA criterion at 2 separate assessments obtained at least 24 hours apart, with no criteria failures or more than 1 missed scheduled visit in between. Additionally, all intervals in which the criteria were met must overlap for at least 1 day.
| Participants | Ravulizumab |
|---|---|
| Participants With Thrombotic Microangiopathy (TMA) Response | 7 |
Time to TMA response was defined as the time from first infusion to the first time point at which all criteria for TMA response was met. Participants were assigned as responders at the time of their TMA response and were censored at the earlier of last assessment with all 3 TMA response components available (including measurements collected after treatment discontinuation), or death if they did not respond by then. TMA response required the following: 1. Normalization of platelet count (defined as platelet count ≥ 50000 mm\^3 or \>=50% increase in platelet count) without transfusion support during the prior 7 days. 2. Normalization of LDH (defined as LDH ≤ULN) and absence of schistocytes. 3. At least 50% reduction in protein/creatinine ratio from baseline.
| days | Ravulizumab |
|---|---|
| Time to TMA Response During the 26-Week Treatment Period | NA (154.0 to NA) |
Hematologic response required the following: (1) Normalization of platelet count (defined as platelet count ≥ 50000 mm\^3 or \>=50% increase in platelet count) without transfusion support during the prior 7 days and (2) Normalization of LDH (defined as LDH ≤ULN) and absence of schistocytes.
| Participants | Ravulizumab |
|---|---|
| Participants With Hematologic Response | 10 |
Time to Hematologic response was defined as the time from first infusion to the first time point at which all criteria for hematologic response was met. Participants were assigned as responders at the time of their response and were censored at their discontinuation time or at the end of available follow-up if they did not respond by then. Hematologic response required the following: (1) Normalization of platelet count (defined as platelet count ≥ 50000 mm\^3 or \>=50% increase in platelet count) without transfusion support during the prior 7 days and (2) Normalization of LDH (defined as LDH ≤ULN) and absence of schistocytes.
| days | Ravulizumab |
|---|---|
| Time to Hematologic Response During the 26-Week Treatment Period | NA (154.0 to NA) |
Hemoglobin response was defined as the ability to maintain hemoglobin ≥ 10 g/dL without RBC transfusion support. The criterion must have been met at 2 separate assessments obtained at least 24 hours apart, and any measurement in between, and without RBC transfusion support during the prior 7 days.
| Participants | Ravulizumab |
|---|---|
| Participants With Hemoglobin Response | 17 |
Normalization of platelet count was defined as baseline platelet count ≤ 50000 mm\^3 or \> 50000 mm\^3, absolute platelet count \> 50000 mm\^3 or \>=50% increase in platelet count without transfusion support during the prior 7 days.
| Participants | Ravulizumab |
|---|---|
| Participants With Platelet Response | 24 |
Partial response was defined as a participant meeting at least 1, but not all, criteria for TMA response. TMA response required the following: 1. Normalization of platelet count (defined as platelet count ≥ 50000 mm\^3 or \>=50% increase in platelet count) without transfusion support during the prior 7 days. 2. Normalization of LDH, (defined as LDH ≤ULN) and absence of schistocytes. 3. At least 50% reduction in protein/creatinine ratio from baseline.
| Participants | Ravulizumab |
|---|---|
| Participants With Partial TMA Response | 22 |
Loss of response occurred when a participant who had previously achieved a TMA response failed to meet criteria for one or more components of TMA response at a subsequent visit in treatment period. At least one parameter must fail to meet response criteria at 2 separate assessments obtained at least 24 hours apart, and any measurement in between. TMA response required the following: 1. Normalization of platelet count (defined as platelet count ≥ 50000 mm\^3 or \>=50% increase in platelet count) without transfusion support during the prior 7 days. 2. Normalization of LDH (defined as LDH ≤ULN) and absence of schistocytes. 3. At least 50% reduction in protein/creatinine ratio from baseline.
| Participants | Ravulizumab |
|---|---|
| Participants With Loss of TMA Response | 2 |
This analysis includes data for each participant after TMA response through final follow-up. Participants with TMA response who do not experience these events are censored at their end of study date. TMA response required following: 1. Normalization of platelet count (defined as platelet count ≥ 50000 mm\^3 or \>=50% increase in platelet count) without transfusion support during the prior 7 days. 2. Normalization of LDH (defined as LDH ≤ULN) and absence of schistocytes. 3. At least 50% reduction in protein/creatinine ratio from baseline. The estimate is calculated based on Kaplan-Meier method.
| days | Ravulizumab |
|---|---|
| Duration of TMA Response Through Week 52 | NA (22.0 to NA) |
For participants that meet criteria for TMA response during 26-week Treatment Period, TMA relapse is defined as evidence of worsening hematologic and renal dysfunction due to TMA during post-treatment Follow-up Period that requires treatment intervention, as determined by Investigator. TMA response required the following: 1. Normalization of platelet count (defined as platelet count ≥ 50000 mm\^3 or \>=50% increase in platelet count) without transfusion support during the prior 7 days. 2. Normalization of LDH (defined as LDH ≤ULN) and absence of schistocytes. 3. At least 50% reduction in protein/creatinine ratio from baseline.
| Participants | Ravulizumab |
|---|---|
| Participants With TMA Relapse | 0 |
The Kaplan-Meier method was used to measure overall survival estimate. Overall survival was calculated from date of treatment start to date of a documented death event (death due to any cause) or date of censoring. Participants who survived were censored at the earliest of an additional hematopoietic stem cell transplant (HSCT), Week 52, or their last known date alive.
| proportion of participants | Ravulizumab |
|---|---|
| Overall Survival | 0.734 (0.560 to 0.847) |
Cumulative incidence was estimated using a competing risk model. Non-relapse mortality was defined as a participant's death due to any cause during the study, with the exception of death due to underlying disease progression or relapse.
| proportion of participants | Ravulizumab |
|---|---|
| Non-relapse Mortality During the 52-Week Treatment Period | 0.184 (0.079 to 0.322) |
Collected over Day 1 up to Week 52. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment Period: Ravulizumab | 6/41 (14.6%) | 30/41 (73.2%) | 41/41 (100%) |
| Follow-up Period: Ravulizumab | 4/29 (13.8%) | 15/29 (51.7%) | 23/29 (79.3%) |
| Event | Treatment Period: Ravulizumab | Follow-up Period: Ravulizumab |
|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 3/41 | 0/29 |
| Multiple organ dysfunction syndromeGeneral disorders | 3/41 | 0/29 |
| SeizureNervous system disorders | 3/41 | 1/29 |
| PyrexiaGeneral disorders | 2/41 | 2/29 |
| Device related bacteraemiaInfections and infestations | 0/41 | 2/29 |
| InfluenzaInfections and infestations | 0/41 | 2/29 |
| Pericardial effusionCardiac disorders | 2/41 | 0/29 |
| COVID-19Infections and infestations | 2/41 | 0/29 |
| Gastroenteritis clostridialInfections and infestations | 2/41 | 0/29 |
| Septic shockInfections and infestations | 2/41 | 0/29 |
| Event | Treatment Period: Ravulizumab | Follow-up Period: Ravulizumab |
|---|---|---|
| HeadacheNervous system disorders | 11/41 | 3/29 |
| DiarrhoeaGastrointestinal disorders | 10/41 | 2/29 |
| PyrexiaGeneral disorders | 10/41 | 6/29 |
| Abdominal painGastrointestinal disorders | 9/41 | 3/29 |
| VomitingGastrointestinal disorders | 8/41 | 0/29 |
| Alanine aminotransferase increasedInvestigations | 8/41 | 1/29 |
| Aspartate aminotransferase increasedInvestigations | 7/41 | 1/29 |
| HypokalaemiaMetabolism and nutrition disorders | 7/41 | 0/29 |
| CoughRespiratory, thoracic and mediastinal disorders | 7/41 | 4/29 |
| AnaemiaBlood and lymphatic system disorders | 6/41 | 0/29 |
Safety set included all participants who signed the informed consent and received at least 1 dose of ravulizumab.
| Age, Continuous(years) | Ravulizumab |
|---|---|
| Mean | 7.6 ± 5.57 |
| Sex: Female, Male(Participants) | Ravulizumab |
|---|---|
| Female | 21 |
| Male | 20 |
| Ethnicity (NIH/OMB)(Participants) | Ravulizumab |
|---|---|
| Hispanic or Latino | 5 |
| Not Hispanic or Latino | 36 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Ravulizumab |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 11 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 2 |
| White | 22 |
| More than one race | 6 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2020 to primary completion in Nov 2024, 47 months.
Results were first posted in Jan 2026, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ravulizumab
Thrombotic Microangiopathies →
Alexion Pharmaceuticals, Inc. →